MedTrace Logo

Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression

NCT01543139 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-02-09

No results posted yet for this study

Summary

This proposed research is aimed to investigate the efficacy and safety of combined cytidine- and creatine-containing drug and dietary supplement in treating bipolar depression and to evaluate changes in relevant brain biochemical metabolism using magnetic resonance spectroscopy.

Conditions

Interventions

DRUG

Valproate+Cytidine-+Creatine-

Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day

DRUG

Valproate+Cytidine-

Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day

DRUG

Valproate

Valproate: Week0-8: 300mg/day

Sponsors & Collaborators

  • Ewha Womans University

    lead OTHER

Principal Investigators

  • In Kyoon Lyoo, MD, PhD, MMS · Ewha Womans University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-01
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543139 on ClinicalTrials.gov